Aradigm Corporation Share Price

ARDMQ

US0385054004

Biotechnology & Medical Research

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

29/20/29	Aradigm Corporation Went Out of Business	CI
12/20/12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Valuation: Aradigm Corporation

Market Cap	48.85L 42.97L 40.63L 36.85L 69.21L 47Cr 69.61L 4.86Cr 1.88Cr 24Cr 1.83Cr 1.79Cr 77Cr	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	1.28Cr 1.13Cr 1.06Cr 96.54L 1.81Cr 122.85Cr 1.82Cr 13Cr 4.92Cr 63Cr 4.8Cr 4.7Cr 201.45Cr	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

* Estimated data More valuation ratios

Latest news: Aradigm Corporation

29/20/29	Aradigm Corporation Went Out of Business	CI
12/20/12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
27/20/27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
08/20/08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
31/20/31	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
30/20/30	Motion for Asset Sale Approved for Aradigm Corporation	CI
09/20/09	Bidding Procedure Approved for Aradigm Corporation	CI
21/20/21	Motion for Asset Sale Filed by Aradigm Corporation	CI
21/20/21	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
06/19/06	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
31/19/31	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
22/19/22	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19/19/19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

More news

Press Releases: Aradigm Corporation

16/20/16	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/20/05	ARADIGM CORP : Other Events (form 8-K)	AQ
30/20/30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/20/13	ARADIGM CORP : Other Events (form 8-K)	AQ
06/20/06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	+6.73%	-	-	7L
LONZA GROUP AG	+2.64%	+6.45%	+11.87%	+38.40%	4.8TCr
IQVIA HOLDINGS INC.	+0.22%	+0.40%	+50.91%	+37.06%	4.45TCr
REVOLUTION MEDICINES, INC.	-1.58%	+4.66%	+359.34%	+614.38%	4.39TCr
BEONE MEDICINES AG	+1.70%	+0.36%	+12.56%	+99.27%	4.1TCr
CELLTRION, INC.	+0.51%	-1.71%	+5.18%	+46.87%	2.99TCr
MEDPACE HOLDINGS, INC.	-0.48%	-1.32%	+23.98%	+150.01%	1.73TCr
TEMPUS AI, INC.	+0.08%	+9.03%	+8.41%	-	1.53TCr
EUROFINS SCIENTIFIC SE	+1.76%	+0.85%	+29.13%	+48.42%	1.53TCr
ASCENDIS PHARMA A/S	+1.97%	-3.17%	-	-	1.48TCr
Average	+0.68%	+2.14%	+62.67%	+147.77%	2.7TCr
Weighted average by Cap.	+0.74%	+1.89%	+79.47%	+163.79%

See all sector performances

Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
ARDMQ Stock

As early as today, start finding the best investment opportunities!

	2016	2017
Net sales	2L 2L 2L 1L 3L 1.87Cr 3L 19.42L 7L 95.52L 7L 7L 3.07Cr	1.45Cr 1.27Cr 1.2Cr 1.09Cr 2.05Cr 138.85Cr 2.06Cr 14Cr 5.56Cr 71Cr 5.43Cr 5.31Cr 227.68Cr
Net income	-3.29Cr -2.9Cr -2.74Cr -2.48Cr -4.67Cr -316.18Cr -4.69Cr -33Cr -13Cr -161.34Cr -12Cr -12Cr -518.45Cr	-1.07Cr -94.15L -89.03L -80.75L -1.52Cr -102.76Cr -1.53Cr -11Cr -4.12Cr -52Cr -4.02Cr -3.93Cr -168.5Cr
Net Debt	-93.72L -82.43L -77.94L -70.7L -1.33Cr -90Cr -1.34Cr -9.33Cr -3.6Cr -46Cr -3.52Cr -3.44Cr -147.52Cr	79.13L 69.59L 65.81L 59.69L 1.12Cr 76Cr 1.13Cr 7.88Cr 3.04Cr 39Cr 2.97Cr 2.91Cr 124.55Cr

Aradigm Corporation Share Price

Stocks

ARDMQ

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news: Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile